# Efficacy and Safety of CRT, Durvalumab and Surgery for SST

Source: https://onco.cc/trials/nct04465968/  
OnCo record `nct04465968` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of cisplatin and durvalumab in lung cancer, run by National Cancer Center Hospital East, not yet recruiting.

## Summary

Efficacy and Safety of CRT, Durvalumab and Surgery for SST is a phase 3, interventional study registered as NCT04465968 by National Cancer Center Hospital East, with a registry enrolment figure of 84 participants, started 2020-09-01 and due to reach its primary completion in 2027-08-31. Interventions recorded: Cisplatin; S1; concurrent radiotherapy; Durvalumab; Surgery; Durvalumab. Conditions listed: Superior Sulcus Tumor; Non-small Cell Lung Cancer Stage IIB; Non Small Cell Lung Cancer Stage III. Primary outcome: 3-year overall survival rate (3y-OS). Lung eligibility wording from the registry: "A definite diagnosis of non-small cell lung cancer has been obtained by biopsy from the primary lesion". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: DEEP_OCEAN
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04465968
- Phase: 3
- Setting: Efficacy and Safety of Durvalumab Before and After Operation or Durvalumab as Maintenance Therapy After Chemoradiotherapy Against Superior Sulcus Non-small Cell Lung Cancer
- Sponsor: National Cancer Center Hospital East
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT04465968: https://clinicaltrials.gov/study/NCT04465968

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04465968.json